Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk

Dow Jones04-09

1003 GMT - Roche's sales performance of its eye drug Vabysmo will be closely watched among its 1Q results, Barclays analysts say in a note. They anticipate a U.S. sales slowdown due to potential Medicare funding issues affecting Vabysmo patients. While Roche has outperformed its European peers in the large-cap pharmaceutical sector this year, recent disappointing trial results with its multiple sclerosis drug HD Ocrevus and safety worries regarding its Elevidys treatment for Duchenne Muscular Dystrophy have created headwinds. Barclays expects Roche to reaffirm its full-year guidance, and developments around its experimental oral weight-loss drug orforglipron to move the share price more than its 1Q results. Roche shares fall 6% to 234.80 Swiss francs. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

April 09, 2025 06:03 ET (10:03 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2526681355?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-09 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526681355","market":"hk","top_or_hot":-1,"title":"Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1003 GMT - Roche's sales performance of its eye drug Vabysmo will be closely watched among its 1Q results, Barclays analysts say in a note. They anticipate a U.S. sales slowdown due to potential Medicare funding issues affecting Vabysmo patients. While Roche has outperformed its European peers in the large-cap pharmaceutical sector this year, recent disappointing trial results with its multiple sclerosis drug HD Ocrevus and safety worries regarding its Elevidys treatment for Duchenne Muscular Dystrophy have created headwinds. Barclays expects Roche to reaffirm its full-year guidance, and developments around its experimental oral weight-loss drug orforglipron to move the share price more than its 1Q results. Roche shares fall 6% to 234.80 Swiss francs. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 09, 2025 06:03 ET (10:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's Eye Drug in Focus for 1Q Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's Eye Drug in Focus for 1Q Earnings -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-09 18:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1003 GMT - Roche's sales performance of its eye drug Vabysmo will be closely watched among its 1Q results, Barclays analysts say in a note. They anticipate a U.S. sales slowdown due to potential Medicare funding issues affecting Vabysmo patients. While Roche has outperformed its European peers in the large-cap pharmaceutical sector this year, recent disappointing trial results with its multiple sclerosis drug HD Ocrevus and safety worries regarding its Elevidys treatment for Duchenne Muscular Dystrophy have created headwinds. Barclays expects Roche to reaffirm its full-year guidance, and developments around its experimental oral weight-loss drug orforglipron to move the share price more than its 1Q results. Roche shares fall 6% to 234.80 Swiss francs. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 09, 2025 06:03 ET (10:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2526681355","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526681355","pubTimestamp":1744192980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1003 GMT - Roche's sales performance of its eye drug Vabysmo will be closely watched among its 1Q results, Barclays analysts say in a note. They anticipate a U.S. sales slowdown due to potential Medicare funding issues affecting Vabysmo patients. While Roche has outperformed its European peers in the large-cap pharmaceutical sector this year, recent disappointing trial results with its multiple sclerosis drug HD Ocrevus and safety worries regarding its Elevidys treatment for Duchenne Muscular Dystrophy have created headwinds. Barclays expects Roche to reaffirm its full-year guidance, and developments around its experimental oral weight-loss drug orforglipron to move the share price more than its 1Q results. Roche shares fall 6% to 234.80 Swiss francs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股"},"translate_title":"罗氏眼科药物成为第一季度盈利焦点——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9},"content_text":"1003 GMT - Roche's sales performance of its eye drug Vabysmo will be closely watched among its 1Q results, Barclays analysts say in a note. They anticipate a U.S. sales slowdown due to potential Medicare funding issues affecting Vabysmo patients. While Roche has outperformed its European peers in the large-cap pharmaceutical sector this year, recent disappointing trial results with its multiple sclerosis drug HD Ocrevus and safety worries regarding its Elevidys treatment for Duchenne Muscular Dystrophy have created headwinds. Barclays expects Roche to reaffirm its full-year guidance, and developments around its experimental oral weight-loss drug orforglipron to move the share price more than its 1Q results. Roche shares fall 6% to 234.80 Swiss francs. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 06:03 ET (10:03 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2526681355","isCrawlerRequest":true}